WO2014094659A1 - Process for preparation of meropenem trihydrate crystals - Google Patents

Process for preparation of meropenem trihydrate crystals Download PDF

Info

Publication number
WO2014094659A1
WO2014094659A1 PCT/CN2013/090169 CN2013090169W WO2014094659A1 WO 2014094659 A1 WO2014094659 A1 WO 2014094659A1 CN 2013090169 W CN2013090169 W CN 2013090169W WO 2014094659 A1 WO2014094659 A1 WO 2014094659A1
Authority
WO
WIPO (PCT)
Prior art keywords
meropenem
solution
filtrate
acid
meropenem trihydrate
Prior art date
Application number
PCT/CN2013/090169
Other languages
French (fr)
Chinese (zh)
Inventor
卫宏远
党乐平
魏颖
Original Assignee
浙江海正药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江海正药业股份有限公司 filed Critical 浙江海正药业股份有限公司
Publication of WO2014094659A1 publication Critical patent/WO2014094659A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20Sulfur atoms

Definitions

  • the invention belongs to the field of chemistry and relates to a method for preparing a drug crystal. Background technique
  • the drug was developed by Sumitomo Corporation of Japan. It was marketed outside of Japan by AstraZeneca under the trade names "Merrem” and "Memnem” in 1995. It belongs to the class of ⁇ -lactam antibiotics and carbapenems.
  • the drug has a wide range of antibacterial properties and can be used to treat a variety of different infections, including meningitis and pneumonia. Its antibacterial spectrum and antibacterial activity are similar to those of imipenem, but due to the structure of hydrocarbons with methyl groups.
  • Mycophenolate which is more stable to dehydropeptidase in the kidneys, does not require an enzyme inhibitor, and can reduce the risk of epilepsy compared to imipenem.
  • Peinan antibiotics are a kind of drugs that are difficult to develop and have complicated production processes. They are mainly prepared by chemical synthesis. The synthesis process includes key side chain synthesis and skeleton core synthesis. Crystallization is the purification step necessary for the production process of meropenem, applied to the final stage of production and determines the final quality of the product.
  • US2007197781, CN200610083362.7 discloses a method of adding a large amount of acetone to a crude aqueous solution of meropenem for elution crystallization. Since the solubility of meropenem in water is small, the amount of acetone added is relatively large, resulting in high operating costs, large solvent residues in the product, and safety hazards in the production process. Great question.
  • U.S. Patent No. 2,009,216,101 discloses a method of concentrating an aqueous solution in which melopenem is dissolved in a reverse osmosis membrane, and then adding a lysing agent such as tetrahydrofuran or acetone to obtain meropenem crystals.
  • US2009264643 provides a process for first adding ammonia water to a crude aqueous solution of meropenem, adjusting the pH with citric acid, and adding tetrahydrofuran for elution crystallization. It is cumbersome to understand the process, and tetrahydrofuran belongs to the second class of solvents and should be avoided in the final crystallization process.
  • CN201010232062.7 discloses a method for refining meropenem trihydrate crystal, dissolving crude meropenem in water at a temperature of 30-70 ° C, decolorizing with activated carbon, filtering at 5 ⁇ 3 (TC, cooling to 0 ⁇ ) After crystallization at 10 ° C, the meropenem trihydrate crystals and the filtrate were obtained by filtration, and meropenem was further recovered by adding an organic solvent such as a lower alcohol or a ketone to the filtrate.
  • an organic solvent such as a lower alcohol or a ketone
  • CN201010232096.6 discloses the following crystallization method: Dissolving crude meropenem in water at a temperature of 30-70 ° C, decolorizing with activated carbon, filtering, adding organic solvent to the filtrate, and cooling to -20 ⁇ 0 °C to make the solution A crystal nucleus is formed, and the crystal nucleus is melted, and crystallized by adding an organic solvent, and filtered to obtain a meropenem trihydrate crystal.
  • CN201010275223.0 provides a method for crystallizing meropenem in sterol: after dissolving the crude product in decyl alcohol, performing decolorization, decarbonization, sterilization filtration, adding water and a precipitating agent (alcohol, ketone, ether, The mixture of tetrahydrofuran or a mixture is crystallized, washed with a mixed solvent of water and an alcohol or an ester, and dried to obtain a product.
  • a precipitating agent alcohol, ketone, ether, The mixture of tetrahydrofuran or a mixture is crystallized, washed with a mixed solvent of water and an alcohol or an ester, and dried to obtain a product.
  • CN201110218567.2 provides a method for crystallizing meropenem in aqueous sodium hydroxide solution: the crude product is dissolved in 10% aqueous sodium hydroxide solution, decolorized, filtered, crystallized at 0 ° C, and ethyl acetate is added to the filtrate to recover the beauty. Luo Peinan.
  • meropenem is prone to ring-opening reactions. Under the process conditions described in this document, about 50% of the meropenem raw materials will undergo ring-opening reaction. Therefore, the product obtained by the method is extremely low in yield, high in impurity content, and difficult to implement industrialization. Guarantee the stability of product quality. Summary of the invention
  • the object of the present invention is to provide a preparation method of meropenem trihydrate, which has high yield, high purity, no organic solvent residue, and a preparation method.
  • a method for preparing meropenem trihydrate crystals comprising the steps of:
  • the pH of the lye in step 1) is 7 to 12.
  • the lye is a weak base solution, more preferably selected from the group consisting of ammonia water, sodium carbonate, and sodium hydrogencarbonate solution, and has a mass concentration of 5 to 15%.
  • the lye is a potassium hydroxide or sodium hydroxide solution.
  • the acid solution is selected from the group consisting of hydrochloric acid, 4 acid or acetic acid solution, and the concentration is 10-50%.
  • step 3 adding an acid solution to the filtrate to bring the pH to 4-7.
  • the temperature of the lye in step 1) is 10 to 30 ° C, more preferably 20 to 30 ° C.
  • step 3 the temperature of the temperature-lowering crystallization is -5 to 10. C.
  • step 1) the crude meropenem has a purity of 80 to 90%.
  • the decolorization temperature of step 2) is 10 to 30 °C.
  • step 3 you can choose to add or not add seed crystals.
  • step 3) is: adding acid to the filtrate to pH 6.5 ⁇ 9, adding seed crystals, continuing to add acid to pH 5.5 ⁇ 6.0, cooling to -5 ⁇ 5 °C, stirring and crystallization, filtering Derived from meropenem trihydrate crystals.
  • the preparation method further comprises the step of subjecting the meropenem trihydrate crystal obtained in the step 3) to a cold water rinsing.
  • the present invention Unlike the method described in the relatively similar patent document CN201110218567.2, the present invention strictly controls the pH of the lye used for dissolving the crude meropenem, and greatly reduces the solubility of meropenem in the lye. The probability of a ring-opening reaction with meropenem.
  • the method of the invention adjusts the pH of the solution to acidity, and then cools and crystallizes, thereby avoiding the long-term meropenem in an alkaline environment and reducing the occurrence of meropenem. The reaction plays an important role.
  • the method of the invention has simple process, is easy to be industrialized, avoids the use of organic solvent, and the process is safe and environmentally friendly; in the process, by preferably controlling the temperature in each step, the ring-opening degradation of meropenem is further reduced, and the obtained meropenem trihydrate is obtained. High yield, high purity and stable quality.
  • BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a 200x photomicrograph of the product obtained in Example 1.
  • Figure 2 is an XRD pattern of the product obtained in Example 1.
  • Figure 3 is an RD spectrum of the meropenem trihydrate standard.
  • BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be further illustrated by the following examples. It should be understood that the preparation methods of the embodiments of the present invention are only for explaining the present invention, and are not intended to limit the present invention. The simple improvement of the preparation method of the present invention within the scope of the present invention is within the scope of the present invention. .
  • the resulting product was analyzed as meropenem trihydrate.
  • the appearance of the product is white or off-white needle crystal, 200 times photomicrograph is shown in Figure 1, X D spectrum is shown in Figure 2, and the XRD pattern of meropenem trihydrate standard is shown in Figure 3.
  • the obtained product was analyzed to be meropenem trihydrate, and its appearance, microscopic morphology and XRD pattern were similar to those in Example 1.
  • the obtained product was analyzed to be meropenem trihydrate, and its appearance, microscopic morphology and XRD pattern were similar to those in Example 1.
  • the obtained product was analyzed to be meropenem trihydrate, and its appearance, microscopic morphology and XRD pattern were similar to those in Example 1.
  • the obtained product was analyzed to be meropenem trihydrate, and its appearance, microscopic morphology and XRD pattern were similar to those in Example 1.

Abstract

Disclosed is a process for preparation of meropenem trihydrate crystals, comprising: 1) dissolving crude meropenem in an alkali solution, thus forming a saturated solution of meropenem; 2) adding activated carbon into the saturated solution for decolorizing and filtering to obtain a filtrate; 3) adding an acid solution to the filtrate to adjust the pH of the solution to pH<7, reducing the temperature and crystallizing, filtering to obtain meropenem trihydrate crystals. The process of the present preparation is simple and easy for industrialization. The process is safe and environmental due to avoiding the use of organic solvents. The meropenem trihydrate is obtained with higher yield, higher purity and stable quality.

Description

一种美罗培南三水合物晶体的制备方法  Method for preparing meropenem trihydrate crystal
技术领域 Technical field
本发明属于化学领域, 涉及一种药物晶体的制备方法。 背景技术  The invention belongs to the field of chemistry and relates to a method for preparing a drug crystal. Background technique
三 水合 美 罗 培 南 ( Meropenem trihydrate ) , 化 学 名 称 为 (4R,5S,6S)-3-[[(3S,5S)-5- (二甲基氨甲酰基) -3-吡咯烷]硫] -6-[(lR)-l-羟乙基 ]-4- 曱基 -7-氧 -1-氮汉环 [3.2.0]庚 -2-烯 -2-羧酸三水合物, 分子式为 C17H25N305S'3H20。白色至微黄色结晶性粉末,无臭, CAS号为 119478-56-7。 Meropenem trihydrate, chemical name (4R, 5S, 6S)-3-[[(3S,5S)-5- (dimethylcarbamoyl)-3-pyrrolidine]sulfonate-6 -[(lR)-l-hydroxyethyl]-4-indolyl-7-oxo-1-azanthene ring [3.2.0]hept-2-ene-2-carboxylic acid trihydrate, the molecular formula is C 17 H 25 N 3 0 5 S'3H 2 0. White to slightly yellow crystalline powder, odorless, CAS No. 119478-56-7.
¾口下:  3⁄4 mouth:
Figure imgf000002_0001
Figure imgf000002_0001
该药物由日本住友株式会社开发, 1995 年由阿斯利康以商品名" Merrem" 及" Memnem"在日本以外的地方上市, 属于 β-内酰胺类抗生素, 碳青霉烯的分 类下。 该药物具有非常广泛的抗菌性, 可用于治疗多种不同的感染, 包括脑膜 炎及肺炎等,其抗菌谱和抗菌作用均与亚胺培南相似,但由于结构上带有甲基 的碳氢霉烯, 对肾脏内的脱氢肽酶较稳定, 不需要酶抑制剂, 相比亚胺培南亦 能降低癫痫的风险。  The drug was developed by Sumitomo Corporation of Japan. It was marketed outside of Japan by AstraZeneca under the trade names "Merrem" and "Memnem" in 1995. It belongs to the class of β-lactam antibiotics and carbapenems. The drug has a wide range of antibacterial properties and can be used to treat a variety of different infections, including meningitis and pneumonia. Its antibacterial spectrum and antibacterial activity are similar to those of imipenem, but due to the structure of hydrocarbons with methyl groups. Mycophenolate, which is more stable to dehydropeptidase in the kidneys, does not require an enzyme inhibitor, and can reduce the risk of epilepsy compared to imipenem.
培南类抗生素是目前研发难度大,生产工艺复杂的一类药物, 主要通过化 学全合成来制备,合成工艺过程包括关键侧链合成和骨架母核的合成。结晶作 为美罗培南生产过程必需的纯化步驟,应用于生产的最后阶段, 并决定产品的 最终品质。  Peinan antibiotics are a kind of drugs that are difficult to develop and have complicated production processes. They are mainly prepared by chemical synthesis. The synthesis process includes key side chain synthesis and skeleton core synthesis. Crystallization is the purification step necessary for the production process of meropenem, applied to the final stage of production and determines the final quality of the product.
近几年已有一些公开美罗培南三水合物晶体制备方法的专利。  In recent years, there have been some patents for the preparation of meropenem trihydrate crystals.
US2007197781、 CN200610083362.7公开了一种向美罗培南粗品水溶液中 加入大量丙酮进行溶析结晶的方法。 由于美罗培南在水中的溶解度较小, 因此 加入丙酮的量比较大, 造成操作成本高, 产品溶剂残留大, 生产过程安全隐患 大等问题。 US2007197781, CN200610083362.7 discloses a method of adding a large amount of acetone to a crude aqueous solution of meropenem for elution crystallization. Since the solubility of meropenem in water is small, the amount of acetone added is relatively large, resulting in high operating costs, large solvent residues in the product, and safety hazards in the production process. Great question.
US20090216101 公开了将溶有美罗培南粗品的水溶液通过反向渗透膜浓 缩, 再加入四氢呋喃或丙酮等溶析剂得到美罗培南晶体的方法。  U.S. Patent No. 2,009,216,101 discloses a method of concentrating an aqueous solution in which melopenem is dissolved in a reverse osmosis membrane, and then adding a lysing agent such as tetrahydrofuran or acetone to obtain meropenem crystals.
US2009264643提供了先向美罗培南粗品水溶液中加氨水、 曱酸调节 pH, 再加入四氢呋喃进行溶析结晶的工艺。谅工艺过程繁瑣,且四氢呋喃属于二类 溶剂, 应避免在最后的结晶过程中使用。  US2009264643 provides a process for first adding ammonia water to a crude aqueous solution of meropenem, adjusting the pH with citric acid, and adding tetrahydrofuran for elution crystallization. It is cumbersome to understand the process, and tetrahydrofuran belongs to the second class of solvents and should be avoided in the final crystallization process.
CN201010232062.7公开了一种美罗培南三水合物结晶的精制方法, 将美 罗培南粗品溶解在温度为 30~70°C的水中, 用活性炭脱色, 在 5~3(TC下过滤, 降温到 0〜10°C析晶, 过滤后得到美罗培南三水合物晶体和滤液, 进一步在所 述滤液中加入低级醇或酮等有机溶剂回收美罗培南。  CN201010232062.7 discloses a method for refining meropenem trihydrate crystal, dissolving crude meropenem in water at a temperature of 30-70 ° C, decolorizing with activated carbon, filtering at 5~3 (TC, cooling to 0~) After crystallization at 10 ° C, the meropenem trihydrate crystals and the filtrate were obtained by filtration, and meropenem was further recovered by adding an organic solvent such as a lower alcohol or a ketone to the filtrate.
CN201010232096.6公开了下面的结晶方法: 将美罗培南粗品溶解在温度 为 30~70 °C的水中,用活性炭脱色,过滤后向滤液中加入有机溶剂,降温到 -20~0 °C 使溶液中形成晶核, 再使晶核融化, 加入有机溶剂析晶, 过滤后得到美罗培南 三水合物晶体。  CN201010232096.6 discloses the following crystallization method: Dissolving crude meropenem in water at a temperature of 30-70 ° C, decolorizing with activated carbon, filtering, adding organic solvent to the filtrate, and cooling to -20~0 °C to make the solution A crystal nucleus is formed, and the crystal nucleus is melted, and crystallized by adding an organic solvent, and filtered to obtain a meropenem trihydrate crystal.
CN201010275223.0提供了一种在曱醇中结晶美罗培南的方法: 将粗品溶 于曱醇后, 进行脱色、 除炭、 除菌过滤, 向滤液中加入水与沉淀剂 (醇、 酮、 醚、 四氢呋喃或混合物)的混合液析晶, 用水和醇或酯的混合溶剂洗涤后干燥 得到产品。  CN201010275223.0 provides a method for crystallizing meropenem in sterol: after dissolving the crude product in decyl alcohol, performing decolorization, decarbonization, sterilization filtration, adding water and a precipitating agent (alcohol, ketone, ether, The mixture of tetrahydrofuran or a mixture is crystallized, washed with a mixed solvent of water and an alcohol or an ester, and dried to obtain a product.
CN201110218567.2提供了一种在氢氧化钠水溶液中结晶美罗培南的方法: 将粗品溶于 10%氢氧化钠水溶液, 脱色、 过滤, 在 0°C析晶, 向滤液中加入乙 酸乙酯回收美罗培南。但是, 采用该方法美罗培南容易发生开环反应。 在该文 献记载的工艺条件下,美罗培南原料中将有约 50%发生开环反应, 因而 ΐ亥方法 实际上得到的产品收率极低, 杂质含量很高, 且实施工业化难度较大, 不能保 证产品质量的稳定性。 发明内容  CN201110218567.2 provides a method for crystallizing meropenem in aqueous sodium hydroxide solution: the crude product is dissolved in 10% aqueous sodium hydroxide solution, decolorized, filtered, crystallized at 0 ° C, and ethyl acetate is added to the filtrate to recover the beauty. Luo Peinan. However, with this method, meropenem is prone to ring-opening reactions. Under the process conditions described in this document, about 50% of the meropenem raw materials will undergo ring-opening reaction. Therefore, the product obtained by the method is extremely low in yield, high in impurity content, and difficult to implement industrialization. Guarantee the stability of product quality. Summary of the invention
本发明的目的在于提供一种美罗培南三水合物的制备方法,使所得美罗培 南三水合物产品收率高、 純度高, 无有机溶剂残留, 且制备方法筒单。  The object of the present invention is to provide a preparation method of meropenem trihydrate, which has high yield, high purity, no organic solvent residue, and a preparation method.
本发明的技术方案如下:  The technical solution of the present invention is as follows:
一种美罗培南三水合物晶体的制备方法, 包括以下步骤:  A method for preparing meropenem trihydrate crystals, comprising the steps of:
1 )将美罗培南粗品溶解在碱液中, 形成美罗培南饱和溶液;  1) Dissolving the crude meropenem in an alkali solution to form a saturated solution of meropenem;
2 ) 向所述饱和溶液中加入活性炭脱色, 过滤, 得滤液; 3 )向所述滤液中加酸溶液使 pH<7, 降温析晶, 过滤得美罗培南三水合物 晶体。 2) adding decoloration to the saturated solution, filtering, and obtaining a filtrate; 3) An acid solution is added to the filtrate to adjust the pH to <7, and the crystal is cooled and crystallized, and the meropenem trihydrate crystal is obtained by filtration.
优选地, 步骤 1 )所述碱液的 pH为 7〜12。  Preferably, the pH of the lye in step 1) is 7 to 12.
优选地,所述碱液为弱碱溶液,更优选选自氨水、碳酸钠、碳酸氢钠溶液, 质量浓度为 5〜: 15%。  Preferably, the lye is a weak base solution, more preferably selected from the group consisting of ammonia water, sodium carbonate, and sodium hydrogencarbonate solution, and has a mass concentration of 5 to 15%.
优选地, 所述碱液为氢氧化钾或氢氧化钠溶液。  Preferably, the lye is a potassium hydroxide or sodium hydroxide solution.
优选地, 步骤 3 ) 所述酸溶液选自盐酸、 4酸或醋酸溶液, 质量浓度为 10~50%。  Preferably, the acid solution is selected from the group consisting of hydrochloric acid, 4 acid or acetic acid solution, and the concentration is 10-50%.
优选地, 步驟 3 ) 向所述滤液中加酸溶液使 pH为 4~7。  Preferably, step 3) adding an acid solution to the filtrate to bring the pH to 4-7.
优选地, 步骤 1 )所述碱液的温度为 10~30°C , 更优选为 20~30°C。  Preferably, the temperature of the lye in step 1) is 10 to 30 ° C, more preferably 20 to 30 ° C.
优选地, 步骤 3 )所述降温析晶的温度为 -5〜10。C。  Preferably, step 3) the temperature of the temperature-lowering crystallization is -5 to 10. C.
优选地, 步骤 1 )所述美罗培南粗品的纯度为 80~90%。  Preferably, step 1) the crude meropenem has a purity of 80 to 90%.
优选地, 步骤 2 ) 的脱色温度为 10~30°C。  Preferably, the decolorization temperature of step 2) is 10 to 30 °C.
步骤 3 ) 的步骤中可以选择添加或不添加晶种。  In step 3), you can choose to add or not add seed crystals.
优选地, 步骤 3 )为: 向所述滤液加酸调至 pH6.5~9, 添加晶种, 继续加 酸至 pH5.5~6.0, 降温至 -5~5 °C , 搅拌析晶, 过滤得美罗培南三水合物晶体。  Preferably, step 3) is: adding acid to the filtrate to pH 6.5~9, adding seed crystals, continuing to add acid to pH 5.5~6.0, cooling to -5~5 °C, stirring and crystallization, filtering Derived from meropenem trihydrate crystals.
优选地, 所述制备方法还包括对步骤 3 )所得美罗培南三水合物晶体进行 冷水淋洗的步骤。  Preferably, the preparation method further comprises the step of subjecting the meropenem trihydrate crystal obtained in the step 3) to a cold water rinsing.
与比较接近的专利文献 CN201110218567.2记载的方法不同, 本发明严格 控制了用于溶解美罗培南粗品的碱液的 pH值, 在保证美罗培南在读碱液中具 有较大溶解度的同时, 大大降低了美罗培南发生开环反应的几率。 另外, 在加 入碱液溶解并以活性炭脱色后, 本发明方法将溶液的 pH调至了酸性, 然后降 温析晶,从而避免了美罗培南长时间处于碱性环境下,对降低美罗培南发生开 钚反应起到重要作用。  Unlike the method described in the relatively similar patent document CN201110218567.2, the present invention strictly controls the pH of the lye used for dissolving the crude meropenem, and greatly reduces the solubility of meropenem in the lye. The probability of a ring-opening reaction with meropenem. In addition, after the alkali solution is dissolved and decolorized by the activated carbon, the method of the invention adjusts the pH of the solution to acidity, and then cools and crystallizes, thereby avoiding the long-term meropenem in an alkaline environment and reducing the occurrence of meropenem. The reaction plays an important role.
本发明方法工艺简单, 容易进行工业化实施, 避免了使用有机溶剂, 过程 安全环保;在工艺过程中通过优选控制各步骤中的温度,进一步降低了美罗培 南的开环降解, 获得的美罗培南三水合物收率高, 純度高, 质量稳定。 附图说明 图 1为实施例 1所得产品的 200倍显微照片。  The method of the invention has simple process, is easy to be industrialized, avoids the use of organic solvent, and the process is safe and environmentally friendly; in the process, by preferably controlling the temperature in each step, the ring-opening degradation of meropenem is further reduced, and the obtained meropenem trihydrate is obtained. High yield, high purity and stable quality. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a 200x photomicrograph of the product obtained in Example 1.
图 2为实施例 1所得产品的 XRD图谱。  Figure 2 is an XRD pattern of the product obtained in Example 1.
图 3为美罗培南三水合物标准品的 RD图谱。 具体实施方案 下面通过实施例对本发明作进一步说明。应该理解的是,本发明实施例所 述制备方法仅仅是用于说明本发明, 而不是对本发明的限制,应用本发明的构 思对本发明的制备方法的简单改进都在本发明要求保护的范围内。 Figure 3 is an RD spectrum of the meropenem trihydrate standard. BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be further illustrated by the following examples. It should be understood that the preparation methods of the embodiments of the present invention are only for explaining the present invention, and are not intended to limit the present invention. The simple improvement of the preparation method of the present invention within the scope of the present invention is within the scope of the present invention. .
以下实施例中的试剂均为市售产品, 美罗培南粗品为按照美国专利 The reagents in the following examples are all commercially available products, and the crude product of meropenem is in accordance with the US patent.
US4943569记载的方法制备得到。 The method described in US 4,943,569 is prepared.
实施例 1:  Example 1:
将 12g纯度为 80%的美罗培南粗品加入到 30mi温度为 10Ό的 8%氨水溶 液中, 搅拌至完全溶解, 向所得溶液中加入活性炭 3g, 在 20°C脱色后过滤, 向滤液中加入质量浓度为 10%的盐酸溶液至 pH =6.9, 降温至 10°C搅拌 2h, 过滤, 滤饼以冷水淋洗, 真空干燥, 得到美罗培南三水合物晶体 9.5g。 收率: 79.2%, 纯度(以无水美罗培南计) 为 99.5%。  12 g of crude meropenem with a purity of 80% was added to a 10% aqueous solution of 8% ammonia at a temperature of 10 Torr, stirred until completely dissolved, and 3 g of activated carbon was added to the obtained solution, which was decolorized at 20 ° C, filtered, and mass concentration was added to the filtrate. It was 10% hydrochloric acid solution to pH = 6.9, cooled to 10 ° C and stirred for 2 h, filtered, and the filter cake was rinsed with cold water and dried under vacuum to obtain 9.5 g of meropenem trihydrate crystal. Yield: 79.2%, purity (in terms of anhydrous meropenem) was 99.5%.
所得产品经分析为美罗培南三水合物。该产品外观为白色或类白色针状晶 体, 200倍显微照片如图 1所示, X D图谱如图 2所示, 美罗培南三水合物 标准品的 XRD图谱如图 3所示。  The resulting product was analyzed as meropenem trihydrate. The appearance of the product is white or off-white needle crystal, 200 times photomicrograph is shown in Figure 1, X D spectrum is shown in Figure 2, and the XRD pattern of meropenem trihydrate standard is shown in Figure 3.
实施例 2:  Example 2:
将 40g纯度为 83 %的美罗培南粗品加入到 100ml温度为 20°C的 10%碳酸 钠溶液中, 搅拌至完全溶解, 向所得溶液中加入活性炭 8g, 在 20°C脱色后过 滤, 向滤液中加入 50%的醋酸溶液至 pH =6.1 , 降温至 0°C , 搅拌 2h, 过滤, 滤饼以冷水淋洗,真空干燥,得到美罗培南三水合物晶体 31.8g。收率: 79.5%, 纯度(以无水美罗培南计) 为 99.6%。  40 g of crude meropenem with a purity of 83% was added to 100 ml of a 10% sodium carbonate solution at a temperature of 20 ° C, stirred until completely dissolved, and 8 g of activated carbon was added to the obtained solution, which was decolorized at 20 ° C, filtered, and filtered into the filtrate. Add 50% acetic acid solution to pH = 6.1, cool to 0 ° C, stir for 2 h, filter, filter cake was rinsed with cold water, and dried under vacuum to obtain 31.8 g of meropenem trihydrate crystal. Yield: 79.5%, purity (in terms of anhydrous meropenem) was 99.6%.
所得产品经分析为美罗培南三水合物, 其外观、 显微形态和 XRD图谱与 实施例 1类似。  The obtained product was analyzed to be meropenem trihydrate, and its appearance, microscopic morphology and XRD pattern were similar to those in Example 1.
实施例 3:  Example 3:
将 30g纯度为 90 %的美罗培南粗品加入到 100ml温度为 30°C的 15%碳酸 氢钠溶液中, 搅拌至完全溶解, 向所得溶液中加入活性炭 6g, 在 30°C脱色后 过滤,向滤液中加入 30%的硫酸溶液至 pH =9,加入晶种后继续加酸至 pH =5.8, 降温至 -5°C , 搅拌 2h, 过滤, 滤饼以冷水淋洗, 真空干燥, 得到美罗培南三水 合物晶体 24.2g。 收率: 80.7%, 纯度(以无水美罗培南计)为 99.6%。 30 g of crude meropenem with a purity of 90% was added to 100 ml of a 15% sodium hydrogen carbonate solution at a temperature of 30 ° C, stirred until completely dissolved, and 6 g of activated carbon was added to the obtained solution, and the mixture was decolorized at 30 ° C, and then filtered. Add 30% sulfuric acid solution to pH=9, add seed crystals and continue adding acid to pH=5.8, cool down to -5 °C, stir for 2h, filter, filter cake with cold water, vacuum dry, get meropenem Water The crystal of the compound was 24.2 g. Yield: 80.7%, purity (calculated as anhydrous meropenem) was 99.6%.
所得产品经分析为美罗培南三水合物, 其外观、 显微形态和 XRD图谱与 实施例 1类似。  The obtained product was analyzed to be meropenem trihydrate, and its appearance, microscopic morphology and XRD pattern were similar to those in Example 1.
实施例 4:  Example 4:
将 30g纯度为 85%的美罗培南粗品加入到 100ml温度为 30°C的 5%碳酸钠 溶液中,搅拌至完全溶解,向所得溶液中加入活性炭 6g,在 10°C脱色后过滤, 向滤液中加入 20%的盐酸溶液至 pH =8, 加入晶种后继续加酸至 pH =5.6, 降 温至 0°C , 搅拌 2h, 过滤, 滤饼以冷水淋洗, 真空干燥, 得到美罗培南三水合 物晶体 23.8g。 收率: 79.3%, 纯度(以无水美罗培南计)为 99.5%。  30 g of crude meropenem with a purity of 85% was added to 100 ml of a 5% sodium carbonate solution at a temperature of 30 ° C, stirred until completely dissolved, and 6 g of activated carbon was added to the obtained solution, which was decolorized at 10 ° C, filtered, and filtered into the filtrate. Add 20% hydrochloric acid solution to pH = 8, add seed crystals, continue to add acid to pH = 5.6, cool to 0 ° C, stir for 2 h, filter, filter cake rinsed with cold water, vacuum dried to obtain meropenem trihydrate The crystal was 23.8 g. Yield: 79.3%, purity (calculated as anhydrous meropenem) was 99.5%.
所得产品经分析为美罗培南三水合物, 其外观、 显微形态和 XRD图谱与 实施例 1类似。  The obtained product was analyzed to be meropenem trihydrate, and its appearance, microscopic morphology and XRD pattern were similar to those in Example 1.
实旄例 5:  Example 5:
将 30g纯度为 85%的美罗培南粗品加入到 100ml温度为 30°C的 5%碳酸钠 溶液中,搅拌至完全溶解,向所得溶液中加入活性炭 6g,在 10°C脱色后过滤, 向滤液中加入 20%的盐酸溶液至 pH =6.5, 加入晶种后继续加酸至 pH =5.6, 降温至 0°C , 搅拌 2h, 过滤, 滤饼以冷水淋洗, 真空干燥, 得到美罗培南三水 合物晶体 23.8g。 收率: 79.3%, 纯度(以无水美罗培南计) 为 99.5%。  30 g of crude meropenem with a purity of 85% was added to 100 ml of a 5% sodium carbonate solution at a temperature of 30 ° C, stirred until completely dissolved, and 6 g of activated carbon was added to the obtained solution, which was decolorized at 10 ° C, filtered, and filtered into the filtrate. Add 20% hydrochloric acid solution to pH = 6.5, add seed crystals, continue to add acid to pH = 5.6, cool to 0 ° C, stir for 2 h, filter, filter cake rinsed with cold water, vacuum dried to obtain meropenem trihydrate The crystal was 23.8 g. Yield: 79.3%, purity (calculated as anhydrous meropenem) was 99.5%.
所得产品经分析为美罗培南三水合物, 其外观、 显微形态和 XRD图谱与 实施例 1类似。  The obtained product was analyzed to be meropenem trihydrate, and its appearance, microscopic morphology and XRD pattern were similar to those in Example 1.

Claims

权利要求 Rights request
1. 一种美罗培南三水合物晶体的制备方法, 包括以下步骤: A method for preparing meropenem trihydrate crystals, comprising the steps of:
1)将美罗培南粗品溶解在碱液中, 形成美罗培南饱和溶液;  1) Dissolving the crude meropenem in an alkali solution to form a saturated solution of meropenem;
2) 向所述饱和溶液中加入活性炭脱色, 过滤, 得滤液;  2) adding decolorization to the saturated solution, filtering, and obtaining a filtrate;
3) 向所述滤液中加酸溶液使 pH<7, 降温析晶, 过滤得美罗培南三水合物晶 体。  3) An acid solution is added to the filtrate to adjust the pH to <7, and the meropenem trihydrate crystal is filtered.
2.根据权利要求 1所述的方法,其特征在于,步骤 1 )所述减液的 pH为 7〜12。  The method according to claim 1, wherein the pH of the liquid reduction step is from 7 to 12.
3.根据权利要求 1或 1所述的方法, 其特征在于, 所述碱液选自氨水、 碳 酸钠或碳酸氢钠溶液, ^量浓度为 5~15%。  The method according to claim 1 or 1, wherein the alkali liquid is selected from the group consisting of ammonia water, sodium carbonate or sodium hydrogencarbonate solution, and the concentration is 5 to 15%.
4.根据权利要求 1或 2所述的方法, 其特征在于, 所述碱液为氢氧化钾或 氢氧化钠溶液。  The method according to claim 1 or 2, wherein the alkali solution is a potassium hydroxide or sodium hydroxide solution.
5.根据权利要求 3所述的方法,其特征在于,步骤 3 )所述酸溶液选自盐酸、 硫酸或醋酸溶液, 质量浓度为 10~50%。  The method according to claim 3, wherein the acid solution is selected from the group consisting of hydrochloric acid, sulfuric acid or acetic acid solution at a concentration of 10 to 50%.
6.根据权利要求 5所述的方法, 其特征在于, 步骤 3 )向所述滤液中加酸溶 液使 pH为 4~7。  The method according to claim 5, wherein step 3) adding an acid solution to the filtrate to bring the pH to 4 to 7.
7.根据权利要求 5所述的方法, 其特征在于, 步骤 1 )所述碱液的温度为 10~30°C , 更优选为 20〜30°C。  The method according to claim 5, wherein the temperature of the lye is 10 to 30 ° C, more preferably 20 to 30 ° C.
8.根据权利要求 7所述的方法, 其特征在于, 步驟 3 )所述降温析晶的温度 为 -5~10。C。  The method according to claim 7, wherein the step 3) the temperature of the cooling and crystallization is -5 to 10. C.
9.根据权利要求 1、 2或 8所述的方法, 其特征在于, 步骤 1 )所述美罗培 南粗品的纯度为 80~90%。  The method according to claim 1, 2 or 8, wherein the step 1) the crude meropenem has a purity of 80 to 90%.
10. 据权利要求 1、 2或 8所述的方法, 其特征在于, 步驟 2 )的脱色温度 为 10~30。C。  10. A method according to claim 1, 2 or 8, characterized in that the decolorization temperature of step 2) is from 10 to 30. C.
11.根椐权利要求 8所述的方法, 其特征在于, 步骤 3 )所述滤液添加或不 添加晶种; 添加晶种的情况下, 添加时溶液的 pH为 8~9。  11. The method according to claim 8, wherein: step 3) adding or not seeding the filtrate; and adding the seed crystal, the pH of the solution is 8 to 9 when added.
12.根据权利要求 3所述的方法, 其特征在于, 步骤 3 ) 为: 向所述滤液加 酸调至 pH6.5~9, 添加晶种, 继续加酸至 pH5.5~6.0, 降温至 -5~5°C ,搅拌析晶, 过滤得美罗培南三水合物晶体。 The method according to claim 3, wherein the step 3) is: adding acid to the filtrate to pH 6.5 to 9, adding seed crystals, continuing to add acid to pH 5.5 to 6.0, and cooling to -5~5 °C, stirring and crystallization, The meropenem trihydrate crystals were filtered.
13.根据权利要求 1、 2或 8所述的方法, 其特征在于, 所述方法还包括对 步骤 3) 所得美罗培南三水合物晶体进行冷水淋洗的步骤。  The method according to claim 1, 2 or 8, characterized in that the method further comprises the step of subjecting the meropenem trihydrate crystal obtained in the step 3) to a cold water rinsing step.
PCT/CN2013/090169 2012-12-21 2013-12-20 Process for preparation of meropenem trihydrate crystals WO2014094659A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNCN201210562074.5 2012-12-21
CN2012105620745A CN102977102A (en) 2012-12-21 2012-12-21 Preparation method of meropenem trihydrate crystal

Publications (1)

Publication Number Publication Date
WO2014094659A1 true WO2014094659A1 (en) 2014-06-26

Family

ID=47851493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/090169 WO2014094659A1 (en) 2012-12-21 2013-12-20 Process for preparation of meropenem trihydrate crystals

Country Status (2)

Country Link
CN (1) CN102977102A (en)
WO (1) WO2014094659A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102977102A (en) * 2012-12-21 2013-03-20 卫宏远 Preparation method of meropenem trihydrate crystal
CN107459520A (en) * 2016-06-02 2017-12-12 重庆圣华曦药业股份有限公司 A kind of new high-purity Meropenem trihydrate preparation method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102267997A (en) * 2011-07-15 2011-12-07 海南美兰史克制药有限公司 Meropenem compound and preparation method thereof
CN102336757A (en) * 2011-08-02 2012-02-01 天津市嵩锐医药科技有限公司 Meropenem compound in stable crystal form
WO2012160576A2 (en) * 2011-05-26 2012-11-29 Sequent Anti Biotics Private Limited A process for preparation of meropenem
CN102977102A (en) * 2012-12-21 2013-03-20 卫宏远 Preparation method of meropenem trihydrate crystal

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101914098B (en) * 2010-07-20 2012-08-15 深圳市海滨制药有限公司 Preparation method of Meropenem trihydrate crystals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012160576A2 (en) * 2011-05-26 2012-11-29 Sequent Anti Biotics Private Limited A process for preparation of meropenem
CN102267997A (en) * 2011-07-15 2011-12-07 海南美兰史克制药有限公司 Meropenem compound and preparation method thereof
CN102336757A (en) * 2011-08-02 2012-02-01 天津市嵩锐医药科技有限公司 Meropenem compound in stable crystal form
CN102977102A (en) * 2012-12-21 2013-03-20 卫宏远 Preparation method of meropenem trihydrate crystal

Also Published As

Publication number Publication date
CN102977102A (en) 2013-03-20

Similar Documents

Publication Publication Date Title
CN102924483B (en) Ceftazidime crystal compound, preparation method of compound and pharmaceutical composition of compound in sterile mixed powder form
CN102558182B (en) Ertapenem sodium crystal form E and preparation method thereof
CN101891742B (en) Preparation method of meropenem trihydrate crystal
CN101914098B (en) Preparation method of Meropenem trihydrate crystals
WO2014094659A1 (en) Process for preparation of meropenem trihydrate crystals
CN101941983A (en) Preparation method of high-purity cefoxitin sodium
CN101717365A (en) Method for purification of torasemide and preparation of big crystal form
CN108690050B (en) A kind of purification process of sulbactam
CN108440569B (en) Preparation method of ceftriaxone sodium spherical crystal
CN110128449A (en) 7- phenylacetyl amido -3- desacetoxycephalosporanic acid salt and its preparation method and application
CN106432134A (en) Purifying method for cefacetrile side chain active ester
CA2556659A1 (en) Direct process for the production of the dihydrochloride of an amino acid
CN105111188A (en) Preparation method for esomeprazole magnesium trihydrate crystalline form
CN110105374B (en) Crystallization method of phenylacetyl-7-amino-3-desacetoxy cephalosporanic acid with controllable granularity and crystal habit
CN112645912B (en) Preparation method of high-purity M2 crystal form meclofenol sodium
CN103937866B (en) A kind of preparation method of the ampicillin of improvement
CN112358489A (en) Production method of industrial penicillin sulfoxide product
CN114105988A (en) Synthetic method of ertapenem sodium
CN105315300B (en) A kind of cefoxitin sodium, preparation method and the usage
CN108707158B (en) Method for purifying cefpirome sulfate
CN112142740B (en) Process for the preparation of imipenem
CN113416193A (en) Novel ertapenem sodium crystal form and preparation method thereof
CN110642860A (en) Method for purifying ertapenem sodium
CN109535184B (en) Method for preparing potassium clavulanate from clavulanic acid tert-octylamine
CN108623598A (en) A kind of preparation method of Imipenem intermediate and Imipenem

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13865519

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13865519

Country of ref document: EP

Kind code of ref document: A1